LRMR
$5.34
Larimar Therapeutics
$.34
6.80%
LRMR
Earnings Whisper ®
N/A
4th Quarter December 2022
Consensus:  ($0.61)
Revenue:  N/A
Thursday
Feb 16
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when LRMR reports earnings?
Beat
Meet
Miss

Where is LRMR's stock price going from here?
Up
Flat
Down
Stock chart of LRMR
Analysts
Summary of analysts' recommendations for LRMR
Score
Grade
Pivots
Resistance
$6.05
$5.70
$5.52

$5.17

Support
$4.99
$4.64
$4.46
Tweet
Growth
Description
Larimar Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing treatments for rare diseases. The company's lead product consist CTI-1601, which is in clinical stage. Larimar Therapeutics Inc., formerly known as Zafgen Inc., is based in BALA CYNWYD, Pa.